P21

What is P21?

P21 — written P021 in nearly all of the primary literature — is a neurotrophic and neurogenic tetrapeptide derived from the most biologically active region of ciliary neurotrophic factor (CNTF) by epitope mapping. Its published formula is Ac-DGGL(A)G-NH2: an acetylated aspartate-glycine-glycine-leucine core with a C-terminal glycine carrying an adamantyl group. The adamantane is not decoration. As the originating group puts it, 'adamantylated glycine was added to its C-terminal to increase its blood-brain barrier permeability and decrease its degradation by exopeptidases to make it druggable.' One point of confusion is worth clearing up immediately, because it recurs across secondary sources and earlier versions of this page: P021 is a **tetrapeptide**, not an 11-mer. The 11-residue peptide is **Peptide 6**, P021's direct predecessor, which corresponds to CNTF amino acid residues 146–156. Peptide 6 was the compound that established the pharmacology — a plasma half-life over 6 hours, blood-brain barrier permeability, and a mechanism of competitively inhibiting leukemia inhibitory factor signalling — and P021 is the shortened, adamantylated, orally active descendant. Anything describing P021 itself as an 11-mer, or quoting 'CNTF residues 148–151', has merged the two compounds. The other thing to know is the route. Unlike almost every peptide in this directory, the defining P021 studies did not inject it. The long-duration experiments administered it **orally, mixed into the animals' diet**, in one case continuously for twelve months. Oral activity is P021's single most distinctive pharmacological property and the main reason it was pursued over its injectable predecessor. P21 is also routinely confused with p21(WAF1/Cip1), the cyclin-dependent kinase inhibitor central to cell-cycle arrest and senescence biology. They are unrelated molecules that happen to share a label.

What P21 Is Investigated For

P021's preclinical record is broad, internally consistent, and almost entirely the output of one research programme. Across 3xTg-AD transgenic mice, Ts65Dn Down syndrome mice, aged rats modelling normal cognitive aging, a non-transgenic sporadic-Alzheimer rat model, controlled-cortical-impact traumatic brain injury, and an autism-sera model, the reported pattern repeats: increased dentate gyrus neurogenesis, restored dendritic and synaptic markers, increased BDNF expression with downstream reduction in GSK3β activity, reduced tau hyperphosphorylation, and rescued performance on hippocampus-dependent memory tasks. The twelve-month oral study is genuinely impressive in design — treatment started before overt pathology and continued for a year — and reported reduced tau hyperphosphorylation plus lower soluble Aβ, framed by the authors as disease modification rather than symptomatic benefit. Two things complicate that picture and the page states both plainly. First, the literature is not independent. Khalid Iqbal appears as an author on effectively every P021 paper including the ones most often described as outside replications — the 2026 diffusion-MRI study from the Medical University of South Carolina lists Iqbal and Fei Liu of the originating institute among its authors, and the 2024 Bologna CDKL5 study likewise includes Iqbal. Iqbal holds US patents on P021 and its precursor and is co-founder and Chief Scientific Officer of Phanes Biotech, Inc., which holds a worldwide licence. That is disclosed openly in the papers' competing-interest statements; it is not a hidden conflict. It does mean genuinely independent replication remains close to absent after fifteen years. Second, the record is not uniformly positive. The 2024 CDKL5 deficiency disorder study found P021 restored neuronal proliferation, survival and maturation in CDKL5-knockout cells in vitro, but reported that 'chronic in vivo P021 treatment failed to increase BDNF levels and did not improve neuroanatomical defects in Cdkl5 KO mice, resulting in limited behavioral benefit.' That is the clearest negative in vivo result in the P021 literature, and it came from the collaboration most distant from the originating lab. Against all of this sits one fact that overrides the rest for anyone considering use: P021 has never been administered to a human being in a published clinical trial of any phase.

History & Discovery

The programme began with a problem rather than a molecule. Ciliary neurotrophic factor has genuine procognitive and pro-neurogenic activity, but as a full-length protein it does not cross the blood-brain barrier, has a short half-life, and causes pronounced anorexia — the liability that derailed CNTF's own clinical development in ALS and obesity. The laboratory of Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities, with Inge Grundke-Iqbal, set out to capture the useful activity in a fragment small enough to be druggable. The first product was **Peptide 6**, an 11-residue sequence corresponding to CNTF residues 146–156, reported in 2009–2011. Peptide 6 enhanced dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory in normal adult mice, carried a plasma half-life over 6 hours, crossed the blood-brain barrier, and acted by competitively inhibiting leukemia inhibitory factor signalling. It was delivered as a slow-release bolus implanted subcutaneously. A 2010 study then showed it reversed neurogenic and neuroplastic deficits and cognitive impairment in 3xTg-AD mice — without, at that stage, affecting Aβ or tau pathology. **P021** is the descendant: a tetrapeptide, Ac-DGGL(A)G-NH2, with adamantylated glycine at the C-terminus to improve brain penetration and resist exopeptidases. The decisive advance was oral activity. From 2014 the key studies simply compounded P021 into the animals' diet, enabling the twelve-month treatment protocol that reported reduced tau hyperphosphorylation and lower soluble Aβ alongside the neurogenic and cognitive effects — a shift from symptomatic rescue toward a disease-modification claim. The programme then widened: Down syndrome models with prenatal and early-postnatal dosing windows, a non-transgenic sporadic-Alzheimer rat model, traumatic brain injury, an autism-sera model, age-related macular degeneration in aged rats, and in 2026 a diffusion-MRI microstructure biomarker. Two features of this history deserve emphasis because they shape how much weight the findings carry. The first is commercial: competing-interest statements disclose that Iqbal holds several US patents on P021, its precursor and derivatives, is co-founder and Chief Scientific Officer of Phanes Biotech, Inc., which holds a worldwide licence, and is described as in the process of developing P021 as a therapeutic for Alzheimer's and related disorders. This is disclosed openly in the papers themselves. The second follows from it: Iqbal is an author on effectively the entire literature, including the 2024 Bologna CDKL5 collaboration and the 2026 Medical University of South Carolina imaging study, both of which are sometimes described — including in an earlier version of this page — as independent replications. They are collaborations with the originating lab. After roughly fifteen years and one publication a year, a genuinely independent reproduction of the core neurogenesis and cognition findings has still not appeared, and the compound has not entered human testing.

How It Works

Your brain makes a growth factor called CNTF that encourages new neurons to form, but the whole protein is too large to reach the brain from the bloodstream and causes appetite loss. P21 is a four-amino-acid fragment of the active part of that protein, with a bulky chemical group bolted on so it survives digestion and crosses into the brain. In animals it increases the birth of new neurons in the hippocampus, raises levels of another growth factor called BDNF, and improves memory — and it does this when simply eaten rather than injected.

The mechanistic chain was established first for Peptide 6, the 11-residue predecessor corresponding to CNTF residues 146–156. That compound was shown to competitively inhibit leukemia inhibitory factor (LIF) signalling, to carry a plasma half-life over 6 hours, and to be blood-brain barrier permeable. LIF and CNTF both signal through the gp130 receptor family, and LIF signalling restrains neural progenitor differentiation — so competitive inhibition at that node disinhibits progenitor proliferation and maturation in the dentate gyrus. P021 is the shortened, adamantylated descendant and is generally assumed to inherit this mechanism, though the competitive-LIF-inhibition work was done on the predecessor rather than repeated on P021. Downstream, the most consistently reported P021 effect is increased brain-derived neurotrophic factor expression, with the twelve-month oral 3xTg-AD study attributing the observed disease modification to 'increased brain derived neurotrophic factor (BDNF) expression mediated decrease in glycogen synthase kinase-3-β (GSK3β) activity.' Because GSK3β is a principal tau kinase, that pathway supplies a coherent explanation for the reduced tau hyperphosphorylation reported across models, and connects a neurogenic compound to a pathology-modifying claim rather than a purely symptomatic one. Reported effects on amyloid were weaker and the authors framed them as consistent with reduced Aβ generation rather than enhanced clearance. The adamantane group does double duty: it raises lipophilicity to assist blood-brain barrier transit, and it blocks exopeptidase degradation at the C-terminus. Together with the N-terminal acetylation this is what makes a four-residue peptide survive the gut and reach the brain — the property that distinguishes P021 from essentially every other peptide on this site. One mechanistic claim that has circulated about P021, including in an earlier version of this page, should be treated with caution: that it 'does not activate STAT3 signalling in the hypothalamus,' offered as the explanation for the absence of CNTF's anorectic effect. The absence of weight loss is well documented. The specific hypothalamic-STAT3 selectivity claim is not clearly sourced in the primary literature, and work on the predecessor peptide describes modulation of the CNTF/JAK/STAT pathway alongside LIF signalling rather than clean avoidance of it. The honest position is that P021 reproducibly avoids the weight loss; why it does so is not settled.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about P21:

• 01Any human clinical trial. No published Phase 1, 2 or 3 study has tested P021 in humans for safety, pharmacokinetics, dose-response or efficacy, and ClinicalTrials.gov holds no record. After approximately fifteen years of continuous preclinical publication and an active patent estate, this is the single most conspicuous gap.
• 02Genuinely independent replication. Khalid Iqbal is an author on effectively the entire P021 literature, including the 2024 University of Bologna CDKL5 study and the 2026 Medical University of South Carolina imaging study that are sometimes described as outside work — both are collaborations with the originating lab. No fully independent group has reproduced the core neurogenesis and cognition findings.
• 03Reconciling the one clear in vivo failure. The 2024 CDKL5 study found P021 effective in CDKL5-knockout neuronal cells but reported that chronic in vivo treatment failed to raise BDNF and did not improve neuroanatomy, with only limited behavioural benefit. Whether this reflects a disease-model boundary, a dosing-window issue as the authors suggest, or a limit on the BDNF mechanism itself is unresolved.
• 04Human pharmacokinetics and bioavailability. Oral activity in rodents is well established and is the compound's distinguishing feature, but no human absorption, distribution or brain-penetration data exists, and no study has compared oral against any parenteral route in any species.
• 05Mechanistic confirmation in P021 itself. Competitive inhibition of leukemia inhibitory factor signalling was demonstrated for the predecessor Peptide 6 and is inherited by assumption rather than re-demonstrated for the tetrapeptide. The claim that P021 avoids hypothalamic STAT3 activation — the usual explanation offered for the absence of anorexia — is not clearly sourced in the primary literature.
• 06Long-term safety of sustained neurogenesis promotion. Theoretical concerns about tumorigenicity, ectopic neurogenesis and altered seizure threshold have not been tested over durations relevant to chronic human use in any species.
• 07Comparative efficacy. The one published head-to-head compares CNTF-derived peptides against cerebrolysin as a class rather than isolating P021, and there is no comparison against semax, BDNF mimetics or small-molecule TrkB agonists.
• 08Effects in healthy adults. The entire preclinical programme uses disease or aging models; whether P021 produces measurable cognitive enhancement in a healthy nervous system is untested, which is precisely the use case the research-chemical market sells it for.

Forms & Administration

There is no human formulation. In the published animal literature P021 is administered **orally, compounded into the diet**, which is how the long-duration 3xTg-AD, cognitive-aging and Down syndrome studies were run — in one case continuously for twelve months. The predecessor Peptide 6 was delivered as a slow-release bolus implanted subcutaneously. No published study uses intraperitoneal or intranasal administration of P021, despite both routes being widely asserted in secondary sources. Material sold through research-chemical channels is typically lyophilised powder labelled for non-human research use, with no identity verification, no purity specification and no chain of custody back to an academic synthesis batch. There is no pharmaceutical-grade P021 and no compounding pathway.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

P021 has never been tested in humans in a published clinical trial and is not approved for any indication in any jurisdiction. Every claim about effective doses or expected effects in people is inference from rodent studies. Note also that an active commercial development programme exists, which means material circulating through research-chemical channels has no relationship to whatever formulation a sponsor might eventually test.

Timeline of Effects

Common Questions

Who P21 Is NOT For

Drug & Supplement Interactions

There are no published clinical drug-interaction studies for P21 in humans, because there are no published clinical studies of any kind. What follows is mechanistic inference, not documented interaction data. The most plausible theoretical concerns involve other agents acting on neurogenesis or neurotrophin signalling. SSRIs and SNRIs upregulate BDNF and adult hippocampal neurogenesis, which is the same downstream node P021 is reported to act through; co-administration could in principle be additive or saturating, and neither outcome has been characterised. Lithium affects BDNF and inhibits GSK3β — the specific kinase P021 is reported to suppress via BDNF — so the overlap there is unusually direct and unusually unstudied. Antiepileptic drugs that suppress neurogenesis would be expected to oppose the mechanism. With anti-proliferative chemotherapy agents, which suppress neurogenesis as part of their CNS toxicity profile, P021's mechanism is in opposition; co-use has no data and is not advisable in any case for patients in active oncology treatment. Corticosteroids likewise suppress hippocampal neurogenesis and would be expected to partially oppose the effect. One route-specific point: because the published administration route is oral, anything affecting gut absorption or first-pass handling would in principle matter — but no absorption, distribution, metabolism or excretion study of P021 exists in any species at a level that would let anyone reason about this concretely. Absence of documented interaction here reflects the total absence of human study, not an established safety margin.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions